Milton Park presents OBN’s Special Recognition Award
Published on 18 November 2022
Last night we celebrated biotech brilliance from across the UK at The OBN Awards 2022, held in London with Declan Curry is the evening’s compère. The Awards, now in their 14th year, showcase the exciting innovation and achievements of impressive life science companies and are hosted by Milton Park-based, not-for-profit life sciences organisation OBN Ltd.
This year Milton Park was honoured to sponsor the ‘Special Recognition Award’, won by Professor Chris Molloy, CEO at Medicines Discovery Catapult, the independent, not-for-profit R&D provider that has reshaped drug discovery for patient benefit in the UK.
Chris was recognised for his impressive career, greatly contributing to science and innovation development in the UK and in particular across the North West and Greater Manchester. Most notably, Chris has:
- been a key advocator for improving access to innovation data to accelerate drug discovery processes
- relaunched a Manchester-based radiochemistry programme to develop better patient therapies
- became the founding Director of the largest UK diagnostics project, Lighthouse Lab
- chaired the industry-governmental consortium that increased the UK’s lateral flow test manufacturing capacity by twenty-fold during the pandemic
When announcing the winner, Philip Campbell, Commercial Director at MEPC Milton Park, said:
“In a career that has spanned over 30 years, our winner tonight is a true champion for supporting the needs of early-stage R&D companies across the life sciences industry. He cut his teeth in internal large pharma, before taking the reigns as the first CEO of the Medicines Discovery Catapult in 2014… I think you’ll all know who we are now talking about!”
Congratulations Chris and thank you OBN for hosting a fantastic evening of celebrations!